TYKERB

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tykerb</td>
<td>lapatinib</td>
<td>Calendar Year</td>
</tr>
</tbody>
</table>

Approvable Criteria:

- Tykerb is being prescribed by, or in consultation with, an oncologist; AND

- Tykerb is being used in combination with:
  - Xeloda (capecitabine), for the treatment of members with advanced or metastatic breast cancer whose tumors over express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab (Herceptin).
  - Femara (letrozole), for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that over expresses the HER2 receptor for whom hormonal therapy is indicated.

Approve for Calendar Year.

**SELF-ADMINISTERED – RX ONLY**

**SPECIALTY PHARMACY PRODUCT**

The recommended dosage of Tykerb for advanced or metastatic breast cancer in 1,250 (5 tablets) given orally once daily on Days 1-21 continuously in combination with Xeloda 2,000mg/m²/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle.

The recommended dose of Tykerb for hormone receptor positive, HER2 positive metastatic breast cancer in 1,500mg (6 tablets) given orally once daily continuously in combination with Femara 2.5mg once daily.

*For Baptist Health Plan to recognize a chemotherapy regimen as an accepted approach to treatment it must be included in the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®).*

*References:*